A bipartisan parliamentary forum has warned that funding shortages and administrative delays under India's rare disease policy are disrupting life-saving treatment
The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026
The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management
University College London sees a 19-26% surge in Indian student enrolments for 2026, focusing on partnerships and scholarships instead of a foreign campus
Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales
A leading rare disease group urges India to adopt a Russia-style dedicated fund and tax-based model to ensure sustained treatment support beyond the current ₹50-lakh cap
Birla Estates has tied up with Sikka Group to co-develop a ₹1,600-crore Greater Noida housing project, leveraging new revival policies that allow creditworthy developers to take over stalled projects
WHO has issued its first guidelines recommending GLP-1 drugs for long-term obesity treatment in adults, while stressing equitable access, health system readiness and lifestyle support
Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment
Day 1 of IIT placements saw a surge of top recruiters, with NVIDIA, Amazon, Zomato, Google and Flipkart among those offering high-value roles, as more students opted for final placements over PPOs
